Applicants: Randy S. Bethiel et al.
Application No.: 10/700,936

AMENDMENTS TO THE CLAIMS

Please replace all prior versions and listings of claims with the amended claims as follows:

1. (Previously presented) A compound of formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

$W^1$ is nitrogen or CH, $W^2$ is nitrogen or C-$(U)_pR^U$, and $W^3$ is nitrogen or C-$(V)_qR^V$;

p and q are each independently 0 or 1;

$R^U$ and $R^V$ are each independently R or $Ar^1$;

U and V are each independently a bond or a $C_{1-6}$ alkylidene chain, wherein up to two methylene units of the chain are optionally and independently replaced by CO, $CO_2$, COCO, CONR, OCONR, NRNR, NRNRCO, NRCO, $NRCO_2$, NRCONR, SO, $SO_2$, $NRSO_2$, $SO_2NR$, $NRSO_2NR$, O, S, or NR;

each occurrence of R is independently hydrogen or an optionally substituted $C_1$-$C_4$ aliphatic, or two R bound to the same nitrogen atom are optionally taken together with the nitrogen atom to form a 3-7 membered saturated, partially unsaturated, or fully unsaturated ring having 0-2 additional heteroatoms independently selected from nitrogen, oxygen, or sulfur;

$Ar^1$ is a 5-7 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or

sulfur; wherein $Ar^1$ is optionally substituted with m independent occurrences of Z-$R^5$; wherein m is 0-5, Z is a bond or is a $C_1$-$C_6$ alkylidene chain wherein up to two methylene units of Z are optionally replaced by CO, $CO_2$, COCO, CONR, OCONR, NRNR, NRNRCO, NRCO, $NRCO_2$, NRCONR, SO, $SO_2$, $NRSO_2$, $SO_2NR$, $NRSO_2NR$, O, S, or NR; and each occurrence of $R^5$ is independently hydrogen, an optionally substituted aliphatic, heteroaliphatic, aryl or heteroaryl group, halogen, $NO_2$, CN, OR, SR, $N(R)_2$, NRCOR, $NRCON(R)_2$, $NRCO_2R$, COR, $CO_2R$, OCOR, $CON(R)_2$, $OCON(R)_2$, SOR, $SO_2R$, $SO_2N(R)_2$, $NRSO_2R$, $NRSO_2N(R)_2$, COCOR, or $COCH_2COR$;

$R^1$ and $R^2$ are taken together and fused to ring B to form a heterocyclic moiety selected from one of formulae (a) through (f):




wherein each occurrence of $R^X$ is independently hydrogen, QR, or $Q_nAr^1$; n is zero or one; and Q is an optionally substituted $C_{1-4}$ alkylidene chain wherein one methylene unit of Q is optionally replaced by CO, $CO_2$, COCO, CONR, OCONR, NRNR, NRNRCO, NRCO, $NRCO_2$, NRCONR, SO, $SO_2$, $NRSO_2$, $SO_2NR$, $NRSO_2NR$, O, S, or NR;

$R^3$ is hydrogen, halogen, QR, $Q_nCN$, $Q_nNO_2$, or $Q_nAr^1$; and

$R^4$ is $Ar^1$, or T-$Ar^1$;

wherein T is a $C_{1-2}$ alkylidene chain wherein one methylene unit of T is optionally replaced by CO, $CO_2$, COCO, CONR, OCONR, NRNR, NRNRCO, NRCO, $NRCO_2$, NRCONR, SO, $SO_2$, $NRSO_2$, $SO_2NR$, $NRSO_2NR$, O, S, or NR.

2. (Previously presented) The compound of claim 1, wherein $R^1$ and $R^2$ taken together form the heterocyclic moiety of formula (a) and $R^X$ is hydrogen or optionally substituted $C_{1-6}$ aliphatic.

3. (Original) The compound of claim 1, wherein $R^X$ is hydrogen, methyl, ethyl, propyl, n-butyl, tert-butyl, pentyl, cyclopentyl, hexyl, cyclohexyl, $C_{1-6}$alkyl substituted with $N(R)_2$, or $C_{1-6}$alkyl substituted with $Ar^1$.

4. (Original) The compound of claim 1, wherein $R^X$ is hydrogen, methyl, or $C_{1-2}$alkyl substituted with a group selected from optionally substituted phenyl, pyridyl, morpholino, piperidinyl, or piperazinyl.

5. (Original) The compound of claim 1, wherein $R^3$ is hydrogen, halogen, QR or $QAr^1$, wherein Q is a $C_{1-3}$ alkylidene chain wherein one methylene unit of Q is optionally replaced by -O-, -S-, -NHCO-, or -NR-, and $Ar^1$ is an optionally substituted 5-6 membered saturated, partially unsaturated, or fully unsaturated ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

6. (Original) The compound of claim 1, wherein $R^3$ is hydrogen, OH, $OCH_3$, $OCH_2CH_3$, NHCOMe, $NH_2$, $NH(C_{1-4}$ aliphatic), $N(C_{1-4}$ aliphatic$)_2$, $O(CH_2)_2$morpholin-4-yl, $O(CH_2)_2NH_2$, $O(CH_2)_2NH(C_{1-4}$ aliphatic), $O(CH_2)_2N(C_{1-4}$ aliphatic$)_2$, Br, Cl, or F.

7. (Original) The compound of claim 1, wherein $R^3$ is hydrogen.

8. (Original) The compound of claim 1, wherein $R^4$ is a 6-membered saturated, partially unsaturated, or aryl ring having 0-3 nitrogens, a 9-10 membered bicyclic aryl ring having 0-2 nitrogen atoms, or a 5 membered heteroaryl ring having 2-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein each ring is optionally substituted.

9. (Original) The compound of claim 1, wherein $R^4$ is optionally substituted phenyl, cyclohexyl, naphthyl, pyridyl, pyrimidinyl, triazinyl, thiazolyl, thiadiazolyl, pyrazolyl, isoxazolyl, indazolyl, or benzimidazolyl.

10. (Original) The compound of claim 1, wherein $R^4$ is an optionally substituted phenyl group.

11. (Original) The compound of claim 8, wherein each occurrence of Z is independently a bond or a $C_{1-4}$ alkylidene chain wherein one methylene unit of Z is optionally replaced by -O-, -S-, -$SO_2$-, or -NH-; and each occurrence of $R^5$ is independently hydrogen, $C_{1-6}$ aliphatic, halogen, $NO_2$, OR, $N(R)_2$, or optionally substituted phenyl, pyridyl, or pyrimidinyl.

12. (Previously presented) The compound of claim 8, wherein each occurrence of $ZR^5$ is independently Cl, F, Br, methyl, ethyl, t-butyl, isopropyl, cyclopropyl, nitro, CN, OMe, OEt, $CF_3$, $NH_2$, phenyl, benzyl, benzyloxy, OH, methylenedioxy, $SO_2NH_2$, $CONH_2$, $CO_2Me$, phenoxy, O-pyridinyl, $SO_2$phenyl, nitrophenoxy, aminophenoxy, S-dimethylpyrimidine, NHphenyl, NH-methoxyphenyl, pyridinyl, phenol, chloro-fluoro-phenyl, dimethylaminophenyl, $CF_3$-phenyl, dimethylphenyl, chlorophenyl, fluorophenyl, methoxyphenoxy, chlorophenoxy, ethoxyphenoxy, and fluorophenoxy.

13. (Original) The compound of claim 1, wherein $(U)_pR^U$ and $(V)_qR^V$ are each independently hydrogen. halogen, $NO_2$, CN, OR, SR or $N(R)_2$, or $C_{1-4}$aliphatic optionally substituted with oxo, OR, SR, $N(R)_2$, halogen, $NO_2$ or CN.

Applicants: Randy S. Bethiel et al.
Application No.: 10/700,936

14. (Original) The compound of claim 1, wherein $(U)_pR^U$ and $(V)_qR^V$ are each independently hydrogen, Me, OH, or OMe.

15. (Original) The compound of claim 1, wherein $W^1$ is N or CH and compounds have the structure of Formula **Ia** or **Ib**:



**Ia**



**Ib**

or a pharmaceutically acceptable salt thereof.

16. (Previously presented) The compound of claim 15, wherein $R^4$ is an optionally substituted phenyl group and compounds have the structure of Formula **IIa** or **IIb**:



**IIa**



**IIb**

or a pharmaceutically acceptable salt thereof.

17. (Previously presented) The compound of claim 16, wherein $R^3$ is hydrogen, and compounds have the structure of Formula **IIIa** or **IIIb**:

Applicants: Randy S. Bethiel et al.
Application No.: 10/700,936



IIIa



IIIb

or a pharmaceutically acceptable salt thereof.

18. (Previously presented) The compound of claim 16, wherein $R^3$ is hydrogen, and $R^1$ and $R^2$ taken together form the heterocyclic moiety of formula (a) and compounds have the structure of Formula **IVa** or **IVb**:



IVa



IVb

or a pharmaceutically acceptable salt thereof.

19. (Previously presented) The compound of claim 15, wherein

i) $R^1$ and $R^2$ taken together form the heterocyclic moiety of formula (a); where $R^X$ is defined according to one of the following groups:

(a) hydrogen or optionally substituted $C_{1-6}$aliphatic;

(b) hydrogen, methyl, ethyl, propyl, n-butyl, tert-butyl, pentyl, cyclopentyl, hexyl, cyclohexyl, $C_{1-6}$alkyl substituted with $N(R)_2$, or $C_{1-6}$alkyl substituted with $Ar^1$; or

(c) hydrogen, methyl, or $C_{1-2}$alkyl substituted with a group selected from optionally substituted phenyl, pyridyl, morpholino, piperidinyl, or piperazinyl.

ii) $R^3$ is defined according to one of the following groups:

(a) hydrogen, halogen, QR or $QAr^1$, wherein Q is a $C_{1-3}$ alkylidene chain wherein one methylene unit of Q is optionally replaced by -O-, -S-, -NHCO-, or -NR-, and $Ar^1$ is an optionally substituted 5-6 membered saturated, partially unsaturated, or fully unsaturated ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

(b) hydrogen, OH, $OCH_3$, $OCH_2CH_3$, NHCOMe, $NH_2$, $NH(C_{1-4}$ aliphatic), $N(C_{1-4}$ aliphatic$)_2$, $O(CH_2)_2$morpholin-4-yl, $O(CH_2)_2NH_2$, $O(CH_2)_2NH(C_{1-4}$ aliphatic), $O(CH_2)_2N(C_{1-4}$ aliphatic$)_2$, bromo, chloro, or fluoro; or

(c) hydrogen;

iii) $R^4$ is defined according to one of the following groups:

(a) a 6-membered saturated, partially unsaturated, or aryl ring having 0-3 nitrogens, a 9-10 membered bicyclic aryl ring having 0-2 nitrogens, or a 5 membered heteroaryl ring having 2-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is optionally substituted with $(ZR^5)_m$;

(b) an optionally substituted ring selected from phenyl, cyclohexyl, naphthyl, pyridyl, pyrimidinyl, triazinyl, thiazolyl, thiadiazolyl, pyrazolyl, isoxazolyl, indazolyl, or benzimidazolyl, wherein said ring is optionally substituted with $(ZR^5)_m$; or

(c) an optionally substituted phenyl group, wherein said phenyl group is optionally substituted with $(ZR^5)_m$;

iv) $W^1$, $W^2$ and $W^3$ are defined according to one of the following groups:

(a) $W^1$ is nitrogen or CH, $W^2$ is nitrogen or $C\text{-}(U)_pR^U$, and $W^3$ is nitrogen or $C\text{-}(V)_qR^V$;

(b) $W^1$ is nitrogen or CH, $W^2$ is C-$(U)_pR^U$, and $W^3$ is C-$(V)_qR^V$; or

(c) $W^1$ is nitrogen or CH and $W^2$ and $W^3$ are each CH; and

v) $(U)_pR^U$ and $(V)_qR^V$ groups are defined according to one of the following groups:

(a) hydrogen, halogen, $NO_2$, CN, OR, SR or $N(R)_2$, or $C_{1-4}$aliphatic optionally substituted with oxo, OR, SR, $N(R)_2$, halogen, $NO_2$ or CN;

(b) hydrogen, Me, OH, OMe or $N(R)_2$; or

(c) both $(U)_pR^U$ and $(V)_qR^V$ are hydrogen.

20. (Previously presented) The compound of any one of claims 16, 17, 18 or 19, wherein each occurrence of Z is independently a bond or a $C_{1-4}$ alkylidene chain wherein one methylene unit of Z is optionally replaced by -O-, -S-, $-SO_2-$, or -NH-; and each occurrence of $R^5$ is independently hydrogen, $C_{1-6}$ aliphatic, halogen, $NO_2$, OR, $N(R)_2$, or optionally substituted phenyl, pyridyl, and pyrimidinyl.

21. (Previously presented) The compound of claim 20, wherein each occurrence of $ZR^5$ is independently Cl, F, Br, methyl, ethyl, t-butyl, isopropyl, cyclopropyl, nitro, CN, OMe, OEt, $CF_3$, $NH_2$, phenyl, benzyl, benzyloxy, OH, methylenedioxy, $SO_2NH_2$, $CONH_2$, $CO_2Me$, phenoxy, O-pyridinyl, $SO_2$phenyl, nitrophenoxy, aminophenoxy, S-dimethylpyrimidine, NHphenyl, NH-methoxyphenyl, pyridinyl, phenol, chloro-fluoro-phenyl, dimethylaminophenyl, $CF_3$-phenyl, dimethylphenyl, chlorophenyl, fluorophenyl, methoxyphenoxy, chlorophenoxy, ethoxyphenoxy, or fluorophenoxy.

22. (Previously presented) The compound of claim 18 having the formula **IVa**, wherein $R^X$ is hydrogen or optionally substituted $C_{1-6}$aliphatic; m is 0, 1 or 2; and $ZR^5$ is Cl, F, Br, methyl, ethyl, t-butyl, isopropyl, cyclopropyl, nitro, CN, OMe, OEt, $CF_3$, $NH_2$, phenyl, benzyl, benzyloxy, OH, methylenedioxy, $SO_2NH_2$, $CONH_2$, $CO_2Me$, phenoxy, O-pyridinyl, $SO_2$phenyl, nitrophenoxy, aminophenoxy, S-dimethylpyrimidine, NHphenyl, NH-methoxyphenyl, pyridinyl, phenol, chloro-fluoro-phenyl, dimethylaminophenyl, $CF_3$-phenyl,

dimethylphenyl, chlorophenyl, fluorophenyl, methoxyphenoxy, chlorophenoxy, ethoxyphenoxy, or fluorophenoxy.

23. (Previously presented) The compound of claim 1, selected from one of the following compounds:



**IVa-1**



**IVa-2**



**IVa-3**



**IVa-4**



**IVa-5**



**IVa-6**



**IVa-7**



**IVa-8**



**IVa-9**



**IVa-10**



**IVa-11**



**IVa-12**

Applicants: Randy S. Bethiel et al.
Application No.: 10/700,936



**IVa-13**



**IVa-14**



**IVa-15**



**IVa-16**



**IVa-17**



**IVa-18**



**IVa-19**



**IVa-20**



**IVa-21**



**IVa-22**



**IVa-23**



**IVa-24**

Applicants: Randy S. Bethiel et al.
Application No.: 10/700,936



**IVa-25**



**IVa-26**



**IVa-27**



**IVa-28**



**IVa-29**



**IVa-30**



**IVa-31**



**IVa-32**



**IVa-33**



**IVa-34**



**IVa-35**



**IVa-36**



**IVa-37**

Applicants: Randy S. Bethiel et al.
Application No.: 10/700,936



IVa-38



IVa-39



IVa-40



IVa-41



IVa-42



IVa-43



IVa-44



IVa-45



IVa-46



IVa-47



IVa-48



IVa-49

Applicants: Randy S. Bethiel et al.
Application No.: 10/700,936



IVa-50



IVa-51



IVa-52



IVa-53



IVa-54



IVa-55



IVa-56



IVa-57



IVa-58



IVa-59

Applicants: Randy S. Bethiel et al.
Application No.: 10/700,936



**IVa-60**



**IVa-61**



**IVa-62**



**IVa-63**



**IVa-64**



**IVa-65**



**IVa-66**



**IVa-67**



**IVa-68**

Applicants: Randy S. Bethiel et al.
Application No.: 10/700,936



IVa-69



IVa-70



IVa-71



IVa-72



IVb-1



IVb-2



IVb-3



IVb-4



IVb-5



IVb-6

Applicants: Randy S. Bethiel et al.
Application No.: 10/700,936



**IVb-7**



**IVb-8**



**IVb-9**



**IVb-10**



**IVb-11**



**IVb-12**



**IVb-13**



**IVb-14**



**IVb-15**



**IVb-16**



**IVb-17**



**IVb-18**

Applicants: Randy S. Bethiel et al.
Application No.: 10/700,936



IVb-19



IVb-20



IVb-21



IVb-22



IVb-23



IVb-24



IVb-25



IVb-26



IVb-27



IVb-28



IVb-29



IVb-30

Applicants: Randy S. Bethiel et al.
Application No.: 10/700,936



IVb-31



IVb-32



IVb-33



IVb-34



IVb-35



IVb-36



IVb-37



IVb-38



IVb-39



IVb-40



IVb-41



IVb-42

Applicants: Randy S. Bethiel et al.
Application No.: 10/700,936



**IVb-43**



**IVb-44**



**IVb-45**



**IVb-46**



**IVb-47**



**IVb-48**



**IVb-49**



**IVb-50**



**IVb-51**



**IVb-52**

Applicants: Randy S. Bethiel et al.
Application No.: 10/700,936



IVb-53



IVb-54



IVb-55



IVb-56



IVb-57



IVb-58



IVb-59



IVb-60



IVb-61



IVb-62

Applicants: Randy S. Bethiel et al.
Application No.: 10/700,936



IVb-63



IVb-64



IVb-65



IVb-66



IVb-67



IVb-68



IVb-69



IVb-70



IVb-71

Applicants: Randy S. Bethiel et al.
Application No.: 10/700,936



**or IVb-72.**

24. (Original) A pharmaceutical composition comprising a compound according to claim 1, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

25. (Canceled)

26. (Currently amended) A method of inhibiting JAK-3 kinase activity in a biological sample: [[:]]

~~(a) a patient; or~~

~~(b) a biological sample;~~

which method comprises ~~administering to said patient, or~~ contacting said biological sample with a compound of claim 1 or a composition comprising said compound.

27. (Canceled)

28. (Currently amended) A method of treating or lessening the severity of a ~~The method of claim 27, wherein the~~ disease or disorder [[is]] selected from an allergic or type I hypersensitivity reaction, asthma, transplant rejection, graft versus host disease, rheumatoid arthritis, ~~amyotrophic lateral sclerosis, multiple sclerosis, Familial amyotrophic lateral sclerosis (FALS),~~ or leukemia, ~~or lymphoma~~ comprising administering to a subject in need thereof a compound of claim 1 or a composition comprising said compound.

Applicants: Randy S. Bethiel et al.
Application No.: 10/700,936

29. (Currently amended) The method of claim 28, comprising the further step of administering to said patient an additional therapeutic agent selected from a chemotherapeutic or anti-proliferative agent, ~~a treatment for Alzheimer's Disease, a treatment for Parkinson's Disease, an agent for treating Multiple Sclerosis (MS),~~ a treatment for asthma, ~~an agent for treating schizophrenia,~~ an anti-inflammatory agent, or an immunomodulatory or immunosuppressive agent, ~~a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating destructive bone disorders, an agent for treating liver disease, an agent for treating a blood disorder, or an agent for treating an immunodeficiency disorder,~~ wherein:

said additional therapeutic agent is appropriate for the disease being treated; and

said additional therapeutic agent is administered together with said composition as a single dosage form or separately from said composition as part of a multiple dosage form.